Literature DB >> 9614555

Adenovirus-mediated expression of an elastase-specific inhibitor (elafin): a comparison of different promoters.

J M Sallenave1, Z Xing, A J Simpson, F L Graham, J Gauldie.   

Abstract

This report describes the design and construction of three recombinant adenoviruses of serotype 5 (Ad5) expressing elafin (EL), also called elastase-specific inhibitor. Three promoters were chosen to drive the synthesis of elafin: the small (380 bp) human cytomegalovirus promoter (HCMV), the Ad2 major late promoter (MLP) and the mouse cytomegalovirus (MCMV) promoter. Human alveolar epithelial cells (A549), as well as rat and human primary pulmonary fibroblasts were infected with Ad5-HCMV-EL, Ad5-MLP-EL, Ad5-MCMV-EL and with the control Ad5-dl70/3. The MCMV promoter was the most efficient promoter in all cells studied. MLP was the least efficient promoter Intermediate between MCMV and MLP was HCMV which was able to induce significant amounts of elafin, particularly in human A549 cells. When compared in vivo in rat lungs, results were similar; MCMV was the only promoter which induced significant amounts of elafin as assessed by Northern blot analysis and ELISA, even with a low dose of virus (3 x 10(8) p.f.u.). Our data indicate that the MCMV promoter is the promoter of choice for the strong induction of adenovirus-mediated transgenes in the lung and suggest its suitability both in rodent experimental models and in humans for investigative and therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9614555     DOI: 10.1038/sj.gt.3300610

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  14 in total

1.  Cyclosporine Does Not Prevent Microvascular Loss in Transplantation but Can Synergize With a Neutrophil Elastase Inhibitor, Elafin, to Maintain Graft Perfusion During Acute Rejection.

Authors:  X Jiang; T T Nguyen; W Tian; Y K Sung; K Yuan; J Qian; J Rajadas; J-M Sallenave; N P Nickel; V de Jesus Perez; M Rabinovitch; M R Nicolls
Journal:  Am J Transplant       Date:  2015-02-27       Impact factor: 8.086

2.  Inhibiting lung elastase activity enables lung growth in mechanically ventilated newborn mice.

Authors:  Anne Hilgendorff; Kakoli Parai; Robert Ertsey; Noopur Jain; Edwin F Navarro; Joanna L Peterson; Rasa Tamosiuniene; Mark R Nicolls; Barry C Starcher; Marlene Rabinovitch; Richard D Bland
Journal:  Am J Respir Crit Care Med       Date:  2011-09-01       Impact factor: 21.405

3.  Antimicrobial activity of murine lung cells against Staphylococcus aureus is increased in vitro and in vivo after elafin gene transfer.

Authors:  J W McMichael; A I Maxwell; K Hayashi; K Taylor; W A Wallace; J R Govan; J R Dorin; J-M Sallenave
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

4.  Adenovirus-mediated Cre deletion of floxed sequences in primary mouse cells is an efficient alternative for studies of gene deletion.

Authors:  S Prost; S Sheahan; D Rannie; D J Harrison
Journal:  Nucleic Acids Res       Date:  2001-08-15       Impact factor: 16.971

5.  The ependymal route for insulin-like growth factor-1 gene therapy in the brain.

Authors:  C B Hereñú; W E Sonntag; G R Morel; E L Portiansky; R G Goya
Journal:  Neuroscience       Date:  2009-06-13       Impact factor: 3.590

6.  Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin.

Authors:  J-M Sallenave; G A Cunningham; R M James; G McLachlan; C Haslett
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

7.  Antiviral activity of trappin-2 and elafin in vitro and in vivo against genital herpes.

Authors:  Anna G Drannik; Kakon Nag; Jean-Michel Sallenave; Kenneth L Rosenthal
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

8.  Trappin-2/elafin modulate innate immune responses of human endometrial epithelial cells to PolyI:C.

Authors:  Anna G Drannik; Kakon Nag; Xiao-Dan Yao; Bethany M Henrick; Jean-Michel Sallenave; Kenneth L Rosenthal
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

9.  IL-6-elafin genetically modified macrophages as a lung immunotherapeutic strategy against Pseudomonas aeruginosa infections.

Authors:  Saadé Kheir; Bérengère Villeret; Ignacio Garcia-Verdugo; Jean-Michel Sallenave
Journal:  Mol Ther       Date:  2021-08-08       Impact factor: 11.454

10.  Organ distribution of transgene expression following intranasal mucosal delivery of recombinant replication-defective adenovirus gene transfer vector.

Authors:  Daniela Damjanovic; Xizhong Zhang; Jingyu Mu; Maria Fe Medina; Zhou Xing
Journal:  Genet Vaccines Ther       Date:  2008-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.